As of Feb 16
| +0.34 / +8.50%|
The 3 analysts offering 12-month price forecasts for Galectin Therapeutics Inc have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +84.33% increase from the last price of 4.34.
The current consensus among 3 polled investment analysts is to Buy stock in Galectin Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.